NCT00197054View on ClinicalTrials.gov

Safety, Immunogenicity of RTS,S/AS02A, and RTS,S/AS01B Malaria Vaccines in Malaria-experienced Adults.

PHASE2CompletedINTERVENTIONAL
Enrollment

255

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2006

Conditions
Plasmodium Falciparum
Interventions
BIOLOGICAL

RTS, S/AS01B

0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.

BIOLOGICAL

RTS, S/AS02A

0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.

BIOLOGICAL

Rabipur (Rabies) Vaccine

1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months

Trial Locations (1)

Unknown

U.S. Army Research Unit-Kenya, Kisumu

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

lead

U.S. Army Medical Research and Development Command

FED